Evidence map›Paper›PMID 31718477›Full record

ArticleTumori2019

What could be a cancer mission objective if we join our forces in the fight against cancer?

Thierry Philip, Sakari Karjalainen, Francesco De Lorenzo, Kathi Apostolidis, Claudio Lombardo, Mef Nilbert, Denis Lacombe, Philip Poortmans, Tit Albreht, Pamela Kearns and 1 more

Abstract readEditorial
In one paragraph

Article in Tumori, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Thierry PhilipOrganisation of European Cancer Institutes, Brussels, Belgium.
Sakari KarjalainenAssociation of European Cancer Leagues, Helsinki, Finland.
Francesco De LorenzoEuropean Cancer Patient Coalition, Athens, Greece.
Kathi ApostolidisEuropean Cancer Patient Coalition, Athens, Greece.
Claudio LombardoOrganisation of European Cancer Institutes, Brussels, Belgium.ORCID https://orcid.org/0000-0001-7554-449X
Mef NilbertCancer Prevention Europe, Lyon, France.
Denis LacombeEuropean Organisation for Research and Treatment of Cancer, Brussels, Belgium.
Philip PoortmansEuropean Cancer Organisation, Brussels, Belgium.
Tit AlbrehtInnovative Partnership for Action Against Cancer, Ljubljana, Slovenia.
Pamela KearnsEuropean Society for Paediatric Oncology, Birmingham, UK.
Gilles VassalEuropean Society for Paediatric Oncology, Birmingham, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The European cancer burden is growing rapidly, with an estimated 2 million deaths a year according to the latest research. As almost half of cancers are diagnosed after the age of 65, and considering the aging European population, a tidal wave of cancer cases will sweep across Europe within the coming decades. Without major action, the additional number of annual cancer cases is expected to rise from 4.2 million to 5.2 million by 2040. If we are to reach plateauing numbers by 2040 (as a minimum goal), this would require 0.75% annual reduction in risk and 1% reduction in risk of death. These challenges call for attack from various angles, coordinated efforts, rational strategies, initiatives throughout the cancer trajectory, activities to reduce inequities, and implementation of evidence-based measures. In order to defeat the societal challenges of cancer through innovation, Europe will need to join forces and connect the European Commission and the member states, politicians and citizens, industries and patient associations. A cancer mission should thus unite the public and patient viewpoint to the perspective of cancer professionals. The authors describe a plan that has been agreed upon among some of the major European Cancer organizations and associations. This plan uses a cancer mission as a tool and must deliver robust medical evidence to patients and doctors through high-quality research delivering sustainable and affordable strategies for prevention, treatment, and follow-up.

Indexed as

epidemiologyHematology–oncologymolecular oncologypediatric oncologyprevention

Identifiers

PMID31718477
PMCPMC6952939

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.